Nobel Lecture: Carolyn Bertozzi on Bioorthogonal Chemistry (2022)

Added:

Translational Limitations and the Challenge of True In Vivo Orthogonality

While bioorthogonal chemistry represents a monumental leap in chemical biology, critical scientific perspectives highlight significant translational hurdles when moving these reactions from controlled laboratory environments to complex living organisms. A primary challenge is achieving "true" biological orthogonality; side reactions with endogenous biomolecules, metabolic degradation of reagents, and unexpected systemic toxicity remain persistent issues. Furthermore, the delivery, pharmacokinetics, and relatively slow reaction kinetics of reagents under physiological concentrations limit their therapeutic efficacy in human clinical trials. Many researchers argue that relying on external, synthetic chemical reactions within living systems introduces unpredictable biocompatibility risks. They suggest that genetic engineering, endogenous enzymatic targeting, or highly specific antibody-drug conjugates may offer safer, more reliable, and more scalable clinical alternatives for targeting disease compared to complex chemical labeling techniques.

The fundamentals of 'click chemistry,' specifically the copper-catalyzed azide-alkyne cycloaddition (CuAAC) developed by Sharpless and Meldal.
Basic glycobiology, including the structure, biosynthesis, and physiological roles of glycans (complex carbohydrates) on cell surfaces.
Core principles of organic reaction mechanisms and chemical kinetics, particularly under physiological conditions such as neutral pH and aqueous environments.
The concept of biocompatibility and the biological limitations of using transition-metal catalysts in living systems due to cellular toxicity.
Advanced clinical applications of bioorthogonal chemistry, such as the synthesis of highly targeted Antibody-Drug Conjugates (ADCs) for cancer therapy.
In vivo molecular imaging techniques using positron emission tomography (PET) or fluorescence to track metabolic pathways in living organisms in real-time.
Next-generation bioorthogonal reactions that bypass metal toxicity, including strain-promoted azide-alkyne cycloadditions (SPAAC) and tetrazine-trans-cyclooctene ligations.
The development of glycan-targeted therapeutics, such as editing cell-surface sialic acids to enhance the immune system's ability to detect and destroy cancer cells.
148.7K views2.7Klikes38:38@NobelPrizeOriginal Release: 2022-12-08

Bioorthogonal chemistry is a type of chemical reaction designed to occur in living systems without interfering with biological processes; it involves reactions between synthetic chemical groups (such as azides and cyclooctynes) that neither interact with nor interfere with natural biological molecules, enabling applications like imaging cell surface glycans and developing targeted drug delivery systems for cancer treatment.